These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 23221964)
1. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964 [TBL] [Abstract][Full Text] [Related]
2. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498 [TBL] [Abstract][Full Text] [Related]
3. An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in taiwan. Wu WC; Kuo HK; Yeh PT; Yang CM; Lai CC; Chen SN Am J Ophthalmol; 2013 Jan; 155(1):150-158.e1. PubMed ID: 22967867 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603 [TBL] [Abstract][Full Text] [Related]
6. Reactivation of retinopathy of prematurity after ranibizumab treatment. Wong RK; Hubschman S; Tsui I Retina; 2015 Apr; 35(4):675-80. PubMed ID: 25768252 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of ultra-low-dose (0.1 mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: A case series. Ahmed IS; Hadi AM; Hassan HH Eur J Ophthalmol; 2020 Jan; 30(1):40-47. PubMed ID: 30428702 [TBL] [Abstract][Full Text] [Related]
8. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity]. Tian R; Zhang G; Tang S; Guo J; Tan W Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583 [TBL] [Abstract][Full Text] [Related]
9. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY. Harper CA; Wright LM; Young RC; Read SP; Chang EY Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248 [TBL] [Abstract][Full Text] [Related]
10. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation. Chandra P; Kumawat D; Agarwal D; Chawla R J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435 [TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192 [TBL] [Abstract][Full Text] [Related]
13. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity. Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806 [TBL] [Abstract][Full Text] [Related]
14. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Hoerster R; Muether P; Dahlke C; Mehler K; Oberthür A; Kirchhof B; Fauser S Acta Ophthalmol; 2013 Feb; 91(1):e74-5. PubMed ID: 22672259 [No Abstract] [Full Text] [Related]
15. Comparison of the Efficacy Between Intravitreal Aflibercept and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity. Ekinci DY; Çelik K J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):54-60. PubMed ID: 31972042 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab. Jang JH Sci Rep; 2024 Jul; 14(1):15647. PubMed ID: 38977744 [TBL] [Abstract][Full Text] [Related]
18. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468 [TBL] [Abstract][Full Text] [Related]
19. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants. Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816 [TBL] [Abstract][Full Text] [Related]
20. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies. Park SW; Jung HH; Heo H Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062 [No Abstract] [Full Text] [Related] [Next] [New Search]